QuantiFERON-TB test; interferon gamma release assay (IGRA)
Jump to navigation
Jump to search
Indications
- screening for tuberculosis
- patients who have received BCG*
- patients unlikely to return to have tuberculin skin test read*
* otherwise tuberculin skin testing is recommended[9]
* more specific than tuberculin skin testing in patients with a history of BCG vaccination
* the BCG vaccine does not affect QuantiFERON-TB test results[15]
Contraindications
- diagnosis of tuberculosis
- evaluation of reactivation of latent tuberculosis* (obtain chest X-ray)
- avoid routine combination of tuberculin skin test with interferon gamma release assay[9]
* once positive, test remains positive after treatment for active tuberculosis or latent tuberculosis
Advantages
- no need for 2nd visit
- results available in 24 hours
- appears to better identify latent tuberculosis that is likely to progress than tuberculin skin test[6][7]
- negative predictive value > 99%, > than skin testing
- preferred method of tuberculosis screening for patients who have received BCG either as vaccine or as cancer chemotherapy[8][9]
Disadvantages
- false positives:
- 10 of 14 hospital employees in whom latent TB seemed unlkely, repeat testing was negative
- healthcare employees who test positive, often test negative on repeat testing[11]
- baseline false positives among healthcare workers more frequent (3.8%) than tuberculin skin testing (1.8%)[12]
- test conversion* among healthcare workers more frequent (6.1%) than with tuberculin skin testing (0.9%)[12]
- false positives in low-risk patients
- low CD4 counts in patients with HIV1 infection interfere with ability to react with positive control thus rendering results of testing indeterminate[9]
* no association between test conversion & exposure to tuberculosis[12]
Principle
Measures the release of interferon-gamma from lymphocytes in heparinized blood incubated with two or three tuberculous antigens & control antigens.
FDA-approved.
Methods
includes positive control
Management
- rule out active TB, prior to treatment of latent TB
- chest X-ray indicated for positive QuantiFERON-TB test
More general terms
Additional terms
References
- ↑ Journal Watch 21(23):185, 2001 Mazurek GH et al Comparison of a whole-blood interferon gamma assay with tuberculin skin testing for detecting latent Mycobacterium tuberculosis infection. JAMA 286:1740, 2001 PMID: https://www.ncbi.nlm.nih.gov/pubmed/11594899
- ↑ Mazurek GH, Villarino ME; CDC. Guidelines for using the QuantiFERON-TB test for diagnosing latent Mycobacterium tuberculosis infection. Centers for Disease Control and Prevention. MMWR Recomm Rep. 2003 Jan 31;52(RR-2):15-8. PMID: https://www.ncbi.nlm.nih.gov/pubmed/12583541
Gerberding JL et al, MMWR 2005; 54/RR-15:1 The Centers for Disease Control and Prevention (CDC) Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States http://www.cdc.gov/mmwr/PDF/rr/rr5415.pdf - ↑ Ferrara G et al, Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis. Lancet 2006; 367:1328 PMID: https://www.ncbi.nlm.nih.gov/pubmed/16631911
- ↑ de Perio MA et al Cost-effectiveness of interferon gamma release assays vs tuberculin skin tests in health care workers. Arch Intern Med 2009 Jan 26; 169:179. PMID: https://www.ncbi.nlm.nih.gov/pubmed/19171815
- ↑ Cellestis Limited, Carnegie, Victoria, Australia
- ↑ 6.0 6.1 Diel R et al. Negative and positive predictive value of a whole-blood interferon-gamma-release assay for developing active tuberculosis: An update. Am J Respir Crit Care Med 2011 Jan 1; 183:88 PMID: https://www.ncbi.nlm.nih.gov/pubmed/20802162
Lange C and Rieder HL. Intention to test is intention to treat. Am J Respir Crit Care Med 2011 Jan 1; 183:3. PMID: https://www.ncbi.nlm.nih.gov/pubmed/21193782 - ↑ 7.0 7.1 Fong KS et al. Challenges of interferon-gamma release assay conversions in serial testing of health-care workers in a TB control program. Chest 2012 Jul 1; 142:55. PMID: https://www.ncbi.nlm.nih.gov/pubmed/22796839
Diel R, Loddenkemper R, Nienhaus A. Predictive value of interferon-gamma release assays and tuberculin skin testing for progression from latent TB infection to disease state: a meta-analysis. Chest. 2012 Jul;142(1):63-75 PMID: https://www.ncbi.nlm.nih.gov/pubmed/22490872
Loddenkemper R, Diel R, Nienhaus A. To repeat or not to repeat-that is the question!: Serial testing of health-care workers for TB infection. Chest. 2012 Jul;142(1):10-1. doi:http://dx.doi.org/ 10.1378/chest.12-0045. PMID: https://www.ncbi.nlm.nih.gov/pubmed/22796831 - ↑ 8.0 8.1 Mazurek GH, Jereb J, Vernon A, LoBue P et al Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010. MMWR Recomm Rep. 2010 Jun 25;59(RR-5):1-25. PMID: https://www.ncbi.nlm.nih.gov/pubmed/20577159 corresponding NGC guideline withdrawn Jan 2016
- ↑ 9.0 9.1 9.2 9.3 9.4 Medical Knowledge Self Assessment Program (MKSAP) 16, 17 American College of Physicians, Philadelphia 2012, 2015
- ↑ Ponce de Leon D, Acevedo-Vasquez E, Alvizuri S et al Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population. J Rheumatol. 2008 May;35(5):776-81. Epub 2008 Apr 1. PMID: https://www.ncbi.nlm.nih.gov/pubmed/18398944
- ↑ 11.0 11.1 Slater ML et al. Challenges with QuantiFERON-TB gold assay for large-scale, routine screening of U.S. healthcare workers. Am J Respir Crit Care Med 2013 Oct 15; 188:1005 PMID: https://www.ncbi.nlm.nih.gov/pubmed/23978270
- ↑ 12.0 12.1 12.2 12.3 Dorman SE et al. Interferon-gamma release assays and tuberculin skin testing for diagnosis of latent tuberculosis infection in healthcare workers in the United States. Am J Respir Crit Care Med 2014 Jan 1; 189:77 PMID: https://www.ncbi.nlm.nih.gov/pubmed/24299555
- ↑ McMullen SE et al. Performance of QuantiFERON-TB Gold and tuberculin skin test relative to subjects' risk of exposure to tuberculosis. Clin Infect Dis 2014 May 1; 58 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24585559 <Internet> http://cid.oxfordjournals.org/content/58/9/1260
- ↑ Centers for Disease Control and Prevention Interferon-Gamma Release Assays (IGRAs) - Blood Tests for TB Infection. http://www.cdc.gov/tb/publications/factsheets/testing/igra.htm
- ↑ 15.0 15.1 Yamcy JR, Melchert VE QuantiFERON-TB Gold+ for the Diagnosis of Mycobacterium tuberculosis Infection American Family Physician 2021. Feb 1;103(3):177-178 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33507050 https://www.aafp.org/pubs/afp/issues/2021/0201/p177.html#afp20210201p177-b6
Haas MK, Belknap RW. Diagnostic tests for latent tuberculosis infection. Clin Chest Med. 2019;40(4):829-837 PMID: https://www.ncbi.nlm.nih.gov/pubmed/31731987